Kevin Outterson is Executive Director at CARB-X and Professor of Health and Disability Law at Boston University where he co-directs the Health Law Program.
Kevin also serves as a principal investigator at CARB-X, an international public-private partnership to accelerate global antibacterial innovation. Key partners of CARB-X include the National Institute of Allergy and Infectious Diseases (NIAID) in the US Government as well as the Wellcome Trust and the Bill & Melinda Gates Foundation. He has led CARB-X since August 2016.
Kevin’s research work focuses on the law and economics of antimicrobial resistance. He served as a senior author on many key research reports on antibiotic innovation, including reports by Chatham House, Eastern Research Group (ERG), DRIVE-AB, and the Lancet Commission. Kevin was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before the US congress, parliamentary working groups and the World Health Organization as well as several state legislatures.